Early results of systematic drug susceptibility testing in pulmonary tuberculosis retreatment cases in Cameroon

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Noeske, Jürgen ^a   Voelz, Natascha ^a   Fon, Elisabeth ^b   Abena Foe, Jean Louis ^c  

^a German International Cooperation (GIZ)   (Cameroon)

^b Regional Tuberculosis Control Unit   (Cameroon)

^c National Tuberculosis Control Programme   (Cameroon)

Author keywords

Cameroon; Drug resistant tuberculosis; retreatment; surveillance

Indexed keywords

BACTERIA (MICROORGANISMS);

GATIFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CAMEROON; DRUG EFFECT; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MALE; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PILOT STUDY; RETREATMENT; RETROSPECTIVE STUDY; SPUTUM; TIME;

ADULT; ANTITUBERCULAR AGENTS; CAMEROON; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEASIBILITY STUDIES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; RETREATMENT; RETROSPECTIVE STUDIES; RIFAMPIN; SPUTUM; STREPTOMYCIN; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84858601757     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-160     Document Type: Article

References (25)

1. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO Progress Report 2011. World Health Organization, Geneva: WHO 2011 WHO/HTM/TB/2011.3
2. Global Tuberculosis Control 2010. World Health Organization, http://www.who.int/tb/publications/global-report/2010/en/index.html-accessed December 2010
3. Guidelines for Surveillance of Drug Resistance in Tuberculosis. World Health Organization, Geneva: WHO 4 2009 WHO/HTM/TB/2009.422
4. Global Plan to Stop TB 2006-2015. World Health Organization, Geneva: WHO 2006 (WHO/HTM/STB/2006.35)
5. Treatment of tuberculosis: guidelines. World Health Organization, Geneva: WHO 4 2010 WHO/HTM/TB/2009.420
6. Experience with a 21-month standardized regimen for the treatment of multidrug-resistant tuberculosis in Cameroon. Kuaban C, Noeske J, Nyankiye E, Piubello, Eyangoh S, Int J Tuberc Lung Dis 2009 12 193 PC-94308-06
7. Preliminary outcomes of a 12-month standardized regimen for the treatment of multidrug-resistant tuberculosis in Cameroon. Kuaban C, Noeske J, Abena JL, Ait-Khaled N, Rieder H, Trébucq A, Int J Tuberc Lung Dis 2011 15 Suppl3 192
8. Mesure de la sensibilité du bacille tuberculeux aux drogues antibacillaires par la méthode des proportions. Canetti G, Rist N, Grosset J, RevTuberc Pneumol 1963 27 217 272
9. Mycobacterium tuberculosis complex drug resistance pattern and identification of species causing tuberculosis in the West and Centre regions of Cameroon. Assam-Assam J-P, Penlap VB, Cho-Ngwa F, Tedom J-C, Ane-Anyangwe I, Titanji V-P, BMC Infect Dis 2011 11 94 10.1186/1471-2334-11-94 21496268
10. Identification of MDR-TB in Retreatment Cases in Cameroon and Benin. A preliminary evaluation [abstract]. Noeske J, Kuaban C, Nkamsse P, Fon E, Ouagadougou: Union Conference African Region: A-92252 17 2009
11. MDR-TB surveillance under programme conditions in Cameroon: feasibility, constraints, and results [abstract]. Noeske J, Kuaban C, Sander M, Abuja: Union Conference African Region: A40-3-3-2011 18 2011
12. Impact of resistance to anti-tuberculosis drugs on treatment outcome using World Health Organization standard regimens. Noeske J, Nguenko PN, Trans R Soc Trop Med Hyg 2002 96 429 433 10.1016/S0035-9203(02)90383-4 12497982 (Pubitemid 37362031)
13. Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic Review. Suchindran S, Brouwer ES, Van Rie A, PLoS ONE 2009 4 5561 10.1371/journal.pone.0005561 19440304
14. The Challenge of Discharging Research Ethics Duties in Resource-Constrained Settings. Singh JA, PLoS Med 2011 8 1000421 10.1371/journal.pmed.1000421 21423584
15. Retreatment Tuberculosis Cases: Factors Associated With Drug Resistance and Adverse Outcomes. Kritski AL, Rodrigues de Jesus LS, Andrade MK, Werneck-Barroso E, Vieira MA, Haffner A, Riley LW, Chest 1997 111 1162 1167 10.1378/chest.111.5.1162 9149564 (Pubitemid 27200066)
16. Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC, Jama 2000 283 2537 2545 10.1001/jama.283.19.2537 10815117 (Pubitemid 30324196)
17. Influence of Multidrug Resistance on Tuberculosis Outcomes with Standardized Regimes. Mak A, Thomas A, del Granado M, Zaleskis R, Mouzafarova N, Menzies D, Am J Respir Crit Care Med 2008 178 306 312 10.1164/rccm.200802-240OC 18511706
18. Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, Golubeva V, Portaels F, Van der Stuyft P, Kimerling M, PLoS One 2009 4 7954 10.1371/journal.pone.0007954 19956770
19. Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen. Green E, Obi CL, Nchabeleng M, de Villiers BE, Sein PP, Letsoalo T, Hoosen AA, Bessong PO, Ndip RN, J Health Popul Nutr 2010 28 7 13 20214081
20. Follow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatment. He GX, Xie YG, Wang LX, Borgdorff MW, van der Werf MJ, Fan JH, Yan XL, Li FB, Zhang XZ, Zhao YL, van den Hof S, PLoS One 2010 5 10799 10.1371/journal.pone.0010799 20520720
21. Effectiveness of the Standard WHO Recommended Retreatment Regimen (Category II) for Tuberculosis in Kampala. Jones-Lopez EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, Dryden-Peterson S, Nyakoojo G, Fennelly K, Temple B, Nakubulwa S, Joloba ML, Okwera A, Eisenach KD, McNerney R, Elliott AM, Ellner JJ, Smith PG, Mugerwa RD, Uganda: A Prospective Cohort Study. PLoS Med 2011 8 1000427
22. Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate? Quy HT, Lan NT, Borgdorff MW, Grosset J, Linh PD, Tung LB, van Soolingen D, Raviglione M, Cô NV, Broekmans J, Int J Tuberc Lung Dis 2003 7 631 636 12870683 (Pubitemid 36806857)
23. Limited good and limited vision: multidrug-resistant tuberculosis and global health policy. Kim JY, Shakow A, Mate K, Vandervarker C, Gupta R, Farmer P, Soc Sci Med 2005 61 847 859 10.1016/j.socscimed.2004.08.046 15896895 (Pubitemid 40798579)
24. Drug resistance monitoring: combined rates may be the best indicator for programme performance. Van Deun A, Salim AH, Daru P, Das AP, Aung KJ, Hossain MA, Rigouts L, Fissette K, Portaels F, Int J Tuberc Lung Dis 2004 8 23 30 14974742 (Pubitemid 38120702)
25. Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing. Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M, Clin Infect Dis 2011 52 901 906 10.1093/cid/cir081 21427397